Deutsche Bank’s analysts initiating Arrowhead Research at Buy with a $45 price target. They explain why:
Arrowhead is an early stage platform company that we believe could have the market cap potential of $4-5B. The company’s lead target is ARC-520 for Hepatitis B (HBV).
What a gift, Thank U.
Tech Stock Poised for Strong Growth: Facebook,
Christine Andrews | More Articles March 03, 2014
Twitter Share Unlock Could Cause A 20% Correction
Feb. 16, 2014 2:55 AM ET | About: TWTR
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
So after unleashing my article on Twitter (TWTR) to the public, I got a lot of constructive criticism from the reader base. The most common concern was the impact the share unlock would have. Now for those of youwho don't know, Twitter is allowing 9.9 million shares to be unlocked today (Saturday). On May 6, 2014 an additional 465 million shares will be unlocked.